Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 265 clinical trials
Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer

This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will receive EPI-7386. Since this is the first study of EPI-7386 in humans, there is no information about how it affects people …

bone lesion
progressive disease
metastatic castration-resistant prostate cancer
metastasis
diphosphonates
  • 0 views
  • 19 Feb, 2024
Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Evaluate the safety and tolerability of AMG 509 in adult subjects and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

liver metastasis
progressive disease
metastatic castration-resistant prostate cancer
metastasis
abiraterone
  • 0 views
  • 19 Feb, 2024
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC.

metastatic castration-resistant prostate cancer
metastasis
rimiducid
cancer
prostate cancer
  • 0 views
  • 19 Feb, 2024
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

combined modality therapy
prostatic neoplasms, castration-resistant
docetaxel
testosterone
cancer
  • 0 views
  • 19 Feb, 2024
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

This phase II study investigates how well radium-223 works in treating patients with castration-resistant prostate cancer than has spread to the bones (bone metastases). Prostate cancer is the most common cancer in men and the second leading cause of cancer death. Furthermore, many men with notably advanced disease have been …

metastatic malignant neoplasm
prostate-specific antigen
metastatic castration-resistant prostate cancer
metastasis
dna damage
  • 0 views
  • 19 Feb, 2024